

IMPACT FACTOR 3.4

Indexed in: PubMed



an Open Access Journal by MDPI

# **Diabetes Mellitus: Current Research and Future Perspectives**

Guest Editor:

#### Dr. Roberto Franceschi

Pediatric Unit, S. Chiara Hospital, 38122 Trento, Italy

Deadline for manuscript submissions:

closed (20 February 2024)

## Message from the Guest Editor

Dear Colleagues,

The heterogeneity in age at onset and clinical presentation within the same form of diabetes, differences in the response to treatments in patients with the same phenotype, as well as the variability in the course of the disease require personalized management. The precision medicine approach has been applied to individuals with monogenic diabetes (i.e., MODY, neonatal diabetes) and to type 1 and type 2 diabetes, to select treatments that are most likely to offer benefits and least likely to cause side effects, with improvement of clinical outcomes and economic cost saving.

In the last 10 years, genetic, metabolomic, immunologic, and other sophisticated tests have become less expensive and more widespread; therefore, it is expected that precision medicine will become increasingly applied to diabetes care.

This Special Issue of the *Journal of Personalized Medicine* aims to highlight the current state of precision medicine applied to diabetes, to show some of the latest findings and future perspectives, and to integrate expertise from basic science, clinical, and population-based approaches.







IMPACT FACTOR 3.4





an Open Access Journal by MDPI

### **Editor-in-Chief**

#### Prof. Dr. David Alan Rizzieri

 Novant Health Cancer Institute, Winston-Salem, NC 27103, USA
Division of Hematologic Malignancies and Cellular Therapy, Duke University,

Durham, NC 27710, USA

# **Message from the Editor-in-Chief**

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). JPM is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

### **Author Benefits**

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

**Journal Rank:** JCR - Q2 (*Medicine, General & Internal*) CiteScore - Q2 (*Medicine (miscellaneous*))

### **Contact Us**